Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids

This is a pilot randomized, blinded, placebo-controlled trial of a noninvasive, FDA approved
treatment for uterine fibroids called MR Guided Focused Ultrasound (MRgFUS). Our hypothesis
is that MRgFUS provides superior relief of fibroid symptoms compared with the placebo, a
sham MRgFUS treatment. The investigators will recruit 20 premenopausal women with
symptomatic uterine fibroids to participate in the trial. Participants will be randomly
assigned in a 2:1 ratio to the active treatment arm (MRgFUS) versus the sham MRgFUS
treatment. Participants will remain blinded to their group assignment for 3 months. After 3
months, participants will be told their treatment group and those assigned to the sham group
will be offered complimentary MRgFUS if they desire it. Women will be excluded if they are
inappropriate candidates for a 3 month delay in fibroid treatment, such as those with
significant anemia. The investigators will assess the change from baseline to 1 and 3 months
after treatment in fibroid symptoms, quality of life, fibroid volume measured by MRI, and
hematocrit.